Roche has stipulated a definitive agreement of fusion for the acquisition of Carmot Therapeutics, private American company with center to Berkeley, in California. Carmot’s research and development portfolio includes clinical subcutaneous and oral incretine for the treatment of obesity in patients with and without diabetes, as well as a number of preclinical programs. Incretine are intestinal hormones se...